Résultats de la recherche - Susheel Kumar Singh
- Résultat(s) 1 - 9 résultats de 9
-
1
Construct design, production, and characterization of Plasmodium falciparum 48/45 R0.6C subunit protein produced in Lactococcus lactis as candidate vaccine par Susheel Kumar Singh, Will Roeffen, Ulrik H. Mistarz, Bishwanath Kumar Chourasia, Fen Yang, Kasper D. Rand, Robert W. Sauerwein, Michael Theisen
Publié 2017Artigo -
2
Antibody-Dependent Cellular Inhibition Is Associated With Reduced Risk Against Febrile Malaria in a Longitudinal Cohort Study Involving Ghanaian Children par Régis Wendpayangde Tiendrebeogo, Bright Adu, Susheel Kumar Singh, Morten Hanefeld Dziegiel, Issa Nébié, Sodiomon B. Sirima, Michael Christiansen, Daniel Dodoo, Michael Theisen
Publié 2015Artigo -
3
The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas par Micha Phill Grønholm Jepsen, Prajakta Jogdand, Susheel Kumar Singh, Meral Esen, Michael Christiansen, Saadou Issifou, Aurore Bouyoukou Hounkpatin, Ulysse Ateba-Ngoa, Peter G. Kremsner, Morten Hanefeld Dziegiel, S. Olesen-Larsen, Søren Jepsen, Benjamin Mordmüller, Michael Theisen
Publié 2013Artigo -
4
Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum par Susheel Kumar Singh, Susan Thrane, Bishwanath Kumar Chourasia, Karina Teelen, Wouter Graumans, Rianne Stoter, Geert‐Jan van Gemert, Marga G. van de Vegte-Bolmer, Morten A. Nielsen, Ali Salanti, Adam F. Sander, Robert W. Sauerwein, Matthijs M. Jore, Michael Theisen
Publié 2019Artigo -
5
Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilia... par Barbara Oliveira Baptista, Ana Beatriz Lopes de Souza, Evelyn Kety Pratt Riccio, Cesare Bianco‐Júnior, Paulo Renato Rivas Totino, João Hermínio Martins da Silva, Michael Theisen, Susheel Kumar Singh, Linda Eva Amoah, Marcelo Ribeiro‐Alves, Rodrigo Medeiros de Souza, Josué da Costa Lima‐Junior, Cláudio Tadeu Daniel‐Ribeiro, Lilian Rose Pratt-Riccio
Publié 2022Artigo -
6
A randomized first-in-human phase I trial of differentially adjuvanted Pfs48/45 malaria vaccines in Burkinabé adults par Alfred B. Tiono, Jordan Plieskatt, Alphonse Ouédraogo, Ben Idriss Soulama, Kazutoyo Miura, Edith C. Bougouma, Mohammad Naghizadeh, Aïssata Barry, Jean Baptist B. Yaro, Sem Ezinmègnon, Noelie Henry, Ebenezer Addo Ofori, Bright Adu, Susheel Kumar Singh, Augustin Konkobo, Karin Lövgren Bengtsson, Amidou Diarra, Cecilia Carnrot, Jenny M. Reimer, Amidou Ouédraogo, Moussa Tienta, Carole A. Long, Issa Nébié, Issaka Sagara, Sodiomon B. Sirima, Michael Theisen
Publié 2024Artigo -
7
B-Cell Epitope Mapping of the Plasmodium falciparum Malaria Vaccine Candidate GMZ2.6c in a Naturally Exposed Population of the Brazilian Amazon par Bárbara de Oliveira Baptista, Ana Beatriz Lopes de Souza, Luana Santos Oliveira, Hugo Amorim dos Santos de Souza, Jenifer Peixoto de Barros, Lucas Tavares de Queiroz, Rodrigo Medeiros de Souza, Linda Eva Amoah, Susheel Kumar Singh, Michael Theisen, Rodrigo Nunes Rodrigues‐da‐Silva, Evelyn Kety Pratt Riccio, Paulo Renato Rivas Totino, Josué da Costa Lima‐Junior, Cláudio Tadeu Daniel‐Ribeiro, Lilian Rose Pratt-Riccio
Publié 2023Artigo -
8
Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity par William J. Stone, Joseph J. Campo, André Lin Ouédraogo, Lisette Meerstein‐Kessel, Isabelle Morlais, Dari Da, Anna Cohuet, Sandrine E. Nsango, Colin J. Sutherland, Marga van de Vegte‐Bolmer, Rianne Siebelink‐Stoter, Geert-Jan van Gemert, Wouter Graumans, Kjerstin Lanke, Adam D. Shandling, Jozelyn Pablo, Andy Teng, Sophie Jones, Roos M. de Jong, Amanda Fabra-García, John Bradley, Will Roeffen, Edwin Lasonder, Giuliana Gremo, Evelin Schwarzer, Chris J. Janse, Susheel Kumar Singh, Michael Theisen, Phil Felgner, Matthias Marti, Chris Drakeley, Robert W. Sauerwein, Teun Bousema, Matthijs M. Jore
Publié 2018Artigo -
9
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity par Cyrielle Fougeroux, Louise Goksøyr, Manja Idorn, Vladislav Soroka, Sebenzile K. Myeni, Robert Dagil, Christoph M. Janitzek, Max Søgaard, Kara-Lee Aves, Emma Wenzel Horsted, Sayit Mahmut Erdoğan, Tobias Gustavsson, Jerzy Dorosz, Stine B. Clemmensen, Laurits Fredsgaard, Susan Thrane, Elena Ethel Vidal-Calvo, Paul Khalifé, Thomas Morgan Hulen, Swati Choudhary, Michael Theisen, Susheel Kumar Singh, Asier Garcia-Senosiain, Linda van Oosten, Gorben P. Pijlman, Bettina Hierzberger, Tanja Domeyer, Blanka W. Nalewajek, Anette Strøbæk, Magdalena Skrzypczak, Laura F. Andersson, Søren Buus, Anette Stryhn, Jan Pravsgaard Christensen, Tim J. Dalebout, Kasper Iversen, Lene Holm Harritshøj, Benjamin Mordmüller, Henrik Ullum, Line S. Reinert, Willem A. de Jongh, Marjolein Kikkert, Søren R. Paludan, Thor G. Theander, Morten A. Nielsen, Ali Salanti, Adam F. Sander
Publié 2021Artigo
Outils de recherche:
Sujets similaires
Biology
Immunology
Malaria
Virology
Antibody
Plasmodium falciparum
Medicine
Immunogenicity
Malaria vaccine
Antigen
Epitope
Gene
Genetics
Immune system
Immunity
Internal medicine
Merozoite surface protein
2019-20 coronavirus outbreak
Adjuvant
Adverse effect
Antibody response
Bacteria
Biochemistry
Biotechnology
Capsid
Cohort
Cohort study
Computational biology
Computer science
Coronavirus disease 2019 (COVID-19)